Zydus Cadila gets USFDA nod for Carbidopa tablets

Published On 2018-05-12 06:36 GMT | Update On 2018-05-12 06:36 GMT

Zydus Cadila has received final approval from the US health regulator to market Carbidopa tablets, used for treating symptoms of Parkinson's disease. Parkinson's symptoms include shakiness, stiffness and difficulty in moving.

Zydus Cadila has received the final approval from the USFDA to market Carbidopa tablets (25 mg), the company said in a BSE filing.

The approved product will be manufactured at the group's manufacturing facility at SEZ, Ahmedabad.

The Zydus group has more than 190 approvals and so far filed over 320 abbreviated new drug applications (ANDAs) since it started filings in 2003-04.

Shares of Cadila Healthcare, the listed entity of the group, were up 0.31 percent at Rs 401.75 per scrip on BSE today.

Article Source : PTI

Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2020 Minerva Medical Treatment Pvt Ltd

Comments Policy

Our comments section is governed by our Comments Policy . By posting comments at Medical Dialogues you automatically agree with our Comments Policy , Terms And Conditions and Privacy Policy .

Zydus Cadila gets USFDA nod for Carbidopa tablets

Similar News